Introduction

Autophagy (meaning self-eating) is a highly regulated, multi-step process by which a cell degrades its own cytoplasmic components and organelles (1). The initial stages of autophagy involve the appearance of intracellular double-membrane autophagic vacuoles, named autophagosomes (2). These autophagosomes then fuse with lysosomes to produce the autolysosomes (3). At this point the sequestered bulk cytoplasm, long-lived proteins, and cellular organelles are degraded by hydrolytic enzymes to re-usable molecules, which are released back into the cell for nutrient recycling and energy supplement (4). Under normal conditions, autophagy remains at a low basal level and plays an essential role in the maintenance of cellular homeostasis, but dysregulated autophagy has been associated with metabolic diseases, inflammatory diseases, neurodegeneration, as well as aging (5).

Increasing evidence has also shown that autophagy is involved in oncogenesis. Some data indicate that autophagy is a survival tool for cancer when the degradation of single cells provides energy for the future development of cancer (6). However, when organelles and portions of the cytoplasm are degraded beyond a certain threshold, autophagic cell death is induced (7 – 8). Thus, the excessive and sustained activation of autophagy may limit the survival of cancer cells by digesting essential cytoplasmic components (8). It has been reported that the overexpression of genes encoding core components of autophagic pathways, such as Beclin 1,
Cyclovirobuxine D Induces Autophagy

Cyclovirobuxine D Induces Autophagy can inhibit various cancer types (9), and the induction of autophagy with the use of chemotherapy and radiotherapy helps to remove damaged and mutated cells, thereby reducing tumor size (10). In addition, autophagy is suggested to be an effective approach to alleviate treatment resistance in apoptosis-defective tumor cells (11). Although the definite mechanism underlying autophagic cell death still remains to be elucidated, autophagy can function as a suppressor of cancer, which makes it a promising therapeutic target.

To date, natural products are still present as direct or indirect sources of potential anti-cancer candidates and new chemotherapy adjuvants to enhance the efficacy of chemotherapy and/or to ameliorate its side effects. In China, the medical use of alkaloid-containing traditional herbs has a long history. Growing evidence demonstrates that alkaloids from plants possess anti-cancer activities both in vitro and in vivo by inhibiting proliferation, invasion, and metastasis (12 – 14). Cyclovirobuxine D (CVB-D), an alkaloid component isolated from the roots of Buxus microphylla var. sinica, is a new drug developed in recent years for the treatment of cardiovascular diseases (15 – 16). Clinical application shows that CVB-D has beneficial effects on arrhythmia, angina, coronary heart disease, heart failure, and other cardiovascular disorders (16 – 19). Currently, pharmacological studies on CVB-D have been conducted extensively. However, the role of CVB-D in prevention and treatment of cancer has not been evaluated. In this study, we reported for the first time that CVB-D induced autophagy-associated cell death in MCF-7 human breast cancer cells, which might expand our understanding of the biological activities of CVB-D and support the rational development and exploitation of autophagy inducers in cancer therapy.

Materials and Methods

Reagents
CVB-D (purity ≥ 99%, Aladdin Reagent, Shanghai, China) was dissolved in methanol at 10 mM and stored at 4°C as a stock solution. Its chemical structure is shown in Fig. 1A. The fluorescent dye monodansylcadaverine (MDC) and 3-methyladenine (3-MA) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Primary antibodies against microtubule-associated protein 1 light chain 3 (LC3) and autophagy-related protein 5 (ATG5) were also from Sigma-Aldrich. Primary antibodies against mTOR, phospho-mTOR (Ser2448), Akt, phospho-Akt (Thr308), and phospho-Akt (Ser473) were products of Cell Signaling Technology (Danvers, MA, USA). Anti-α-tubulin primary antibody and all secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was a product of Promega (Madison, WI, USA).

Cell culture
The MCF-7 cell line was purchased from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China). MCF-7 cells were maintained in...
Dulbecco’s modified eagle medium (DMEM) supplemented with 10% v/v fetal bovine serum (FBS) and 1% v/v penicillin/streptomycin (GIBCO, Gaithersburg, MD, USA). Cells were grown at 37°C in a humidified atmosphere consisting of 5% CO₂. The culture medium was replaced with fresh medium every other day. The cells in the exponential phase of growth were used in the experiments. Cells were incubated with various concentrations of CVB-D for the indicated time points and subsequently submitted to the following tests.

**Cell viability**

The cytotoxic effect of CVB-D was determined by MTS assay as described previously (20). MCF-7 cells were seeded at a density of 1.0 × 10⁴ cells/well in 96-well plates. After CVB-D treatment, MTS was added into cell cultures and was incubated for 1 h at 37°C. The absorbance was measured at a wavelength of 490 nm using a microplate reader (Elx800; Bio-Tek, Winooski, VT, USA). Percent viability was defined as the relative absorbance of treated vs. untreated control cells.

**Western blotting**

MCF-7 cells were lysed in RIPA lysis buffer (Beyotime, China) and the protein contents in the supernatant were determined by BCA Protein Assay Kit (Thermo, Waltham, MA, USA). Briefly, the protein was separated by SDS-PAGE gel electrophoresis, and then transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, MA, USA). After blocking with 5% nonfat milk, the membranes were incubated with primary antibodies [diluted 1:1000 for anti-ATG5, 1:2000 for anti-LC3, 1:1000 for anti-mTOR, 1:1000 for anti-phospho-mTOR (Ser2448), 1:1000 for anti-phospho-Akt (Thr308), 1:1000 for anti-phospho-Akt (Ser473), 1:1000 for anti-Akt, 1:5000 for anti-α-tubulin], followed by incubation with appropriate horseradish peroxidase (HRP)-labeled second antibodies (diluted 1:5000). Immunoreactive bands were detected with the Super-Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, USA). The intensity of protein bands was analyzed by LabWorks software (Bio-Rad, Hercules, CA, USA), and α-tubulin was used as a loading control.

**Immunofluorescence assay**

The cytosolic 18 kDa LC3-I form is converted to the autophagosome-associated 16-kDa LC3-II form by conjugation with phosphatidyethanolamine. This conversion is considered a reliable marker of autophagy (21). MCF-7 cells plated on coverslips were fixed in 4% paraformaldehyde and analyzed by using a confocal microscope (Zeiss 710).

**Transmission electron microscopy (TEM)**

To morphologically demonstrate the induction of autophagy in CVB-D–treated tumor cells, the ultrastructural analysis was performed as described previously (22). The cells treated with or without CVB-D were harvested by trypsinization, washed twice with PBS, and fixed with ice-cold glutaraldehyde (3% in 0.1 M cacodylate buffer, pH 7.4) for 30 min. After washing with PBS, the cells were post-fixed in OsO₄ and embedded in epoxy resin. The 50-nm thin sections were stained with uranyl acetate/lead citrate and viewed in an electron microscope (Hitachi 600; Hitachi, Tokyo).

**GFP-LC3 plasmid transfection**

MCF-7 cells expressing LC3 fused to green fluorescent protein (GFP-LC3) were established. Transfection was performed on 100-mm plates with 3 μg GFP-LC3 plasmid using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. GFP-LC3 transfected MCF-7 cells were cultured in complete medium and incubated with or without CVB-D for 24 h. Then, the cells were fixed in 4% paraformaldehyde and analyzed by using a confocal microscope (Zeiss 710).

**MDC staining**

Labeling of autophagic vacuoles with fluorescent compound MDC was performed as reported by others (23). MCF-7 cells following CVB-D treatment were incubated with fresh medium containing 0.05 mM MDC. After incubation for 1 h at 37°C in the dark, cells were subsequently washed 3 times with PBS and fixed with 4% paraformaldehyde for 20 min. Intracellular MDC was measured by a confocal microscope (Zeiss 710).

**Statistical analysis**

Data were presented as the mean ± S.D. Statistical analyses between 2 groups were performed by the unpaired Student’s *t*-test. Differences among groups were tested by one-way analysis of variance (ANOVA) with Tukey’s *post hoc* test. In all cases, differences were considered statistically significant with *P* < 0.05.
Cyclovirobuxine D Induces Autophagy

Results

Effect of CVB-D on cell viability of MCF-7 cell line

To investigate the anti-tumor effect of CVB-D, MCF-7 cells were incubated with 1 to 160 µM CVB-D for the indicated time points. Then the cell viability was detected by MTS assay. As shown in Fig. 1, B and C, CVB-D caused a concentration- and time-dependent inhibition of cell growth. The IC$_{50}$ (concentration resulting in cell viability of 50% of control) of CVB-D for MCF-7 cells was 10 ± 2.51 µM.

Induction of autophagy in MCF-7 cells by CVB-D treatment

Emerging evidence demonstrates that radiation or some chemotherapeutic agents can promote autophagy in various cancer cells (25–28). Thus, we examined if autophagy was induced in MCF-7 cells in response to CVB-D. After exposure to CVB-D (10 µM) for 24 h, MCF-7 cells were collected and the ultrastructure of the cells was detected by TEM. As shown in Fig. 2, A and B, autophagosomes/autolysosomes were often observed in CVB-D–treated MCF-7 cells, but only a few in untreated cells. Most of the autophagosomes contained lamellar structures or residual digested materials. In addition, MCF-7 cells following CVB-D treatment were incubated with MDC, a compound known to label acidic endosomes, lysosomes, and autophagosomes. Little MDC labeling was present in the control group, whereas marked MDC labeling was observed in the MCF-7 cells treated with CVB-D (Fig. 2: C and D).

These results indicated that MCF-7 cells treated with CVB-D for 24 h were in the stage of autophagic process.

Involvement of LC3 and ATG5 in CVB-D–treated MCF-7 cells

LC3, a microtubule-associated protein, is lipidated upon activation of autophagy and associated with the autophagosome membrane (21). To investigate if LC3 was involved in CVB-D–induced autophagy, LC3 puncta formation was assessed by immunofluorescence (IF). The results revealed a clear accumulation of LC3 in the autophagosomes of CVB-D–treated cells (Fig. 3: A and B). In addition, MCF-7 cells were transfected with GFP-LC3 plasmid. Under a confocal microscope, GFP-LC3–transfected cells showed diffuse distribution of green fluorescence in the absence of CVB-D. In contrast, treatment with CVB-D increased a punctate pattern in number and fluorescence intensity, which represented autophagic vacuoles (Fig. 3: C and D), indicating the recruitment of LC3 in CVB-D–induced autophagy. It is well known that the conversion from LC3-I to LC3-II is a reliable marker of autophagy, and ATG5 is essential for autophagosome formation (21). To further assess autophagy activation in this case, MCF-7 cells following CVB-D treatment were incubated with anti-LC3 and anti-ATG5 antibodies, respectively. The results of western blotting revealed that the protein levels of both LC3-II and ATG5 were significantly upregulated in response to CVB-D treatment (Fig. 3: E and F).
3-MA blocked CVB-D–induced autophagy and cell death in MCF-7 cells

To investigate the role of autophagy in CVB-D–induced growth suppression, MCF-7 cells were incubated with the autophagy specific inhibitor 3-MA (5 mM) for 1 h followed by treatment with 10 μM CVB-D. After 24 h, the cells were collected and submitted to western blot analysis. The results showed that the CVB-D–induced increase in protein expression of LC3-II and ATG5 was markedly reversed by 3-MA (Fig. 4: A and B). Inhibition of autophagy by 3-MA was further examined by MDC staining. As shown in Fig. 4C, 3-MA attenuated the accumulation of MDC-labeled fluorescent particles induced by CVB-D. In addition, MTS assay revealed that 3-MA-pretreatment blocked the inhibitive effect of CVB-D on cell viability as compared to CVB-D treatment alone (Fig. 4D). These observations further indicated that CVB-D promoted MCF-7 cells to autophagic death.

CVB-D inhibited Akt/mTOR phosphorylation in MCF-7 cells

It has been demonstrated that inhibition of Akt/mTOR axis stimulates autophagy (31). Akt, as a serine-threonine kinase, shows the constitutive activated state in a variety of cancers, which causes phosphorylation of a wide range of downstream targets, and mTOR plays important roles in regulating many anabolic processes including autophagy and cell survival. In this study, MCF-7 cells were treated with CVB-D (1–100 μM) for 30 min. Western blot analysis showed that the phosphorylation of Akt (Thr308 and Ser473) was attenuated by CVB-D in a concentration-dependent manner, while the total protein level of Akt remained unchanged as compared to the control (Fig. 5: A and B). Moreover, CVB-D suppressed the phosphorylation of mTOR (Ser2448) without affecting its protein expression (Fig. 5: C and D). These results suggested that the Akt/mTOR axis was inhibited by CVB-D.
Discussion

Currently, autophagy is defined as a biological process in which the cell consumes its own cellular components through the lysosome machinery (24). Upon environmental stress, such as nutrient starvation or pathogen infection, cellular autophagy is activated resulting in either adaption and survival or death. Recently, it

Fig. 4. 3-MA blocked CVB-D–induced autophagy and cell death in MCF-7 cells. Cells were incubated with 10 μM CVB-D for 24 h with or without pretreatment with 3-MA (5 mM, for 1 h). A and B) The protein levels of ATG5 and LC3-II were detected by western blotting and α-tubulin was used as an equal loading control. C) The formation of autophagic vacuoles was detected by punctuate MDC labeling, and representative results from 3 independent experiments are shown. Scale bar: 20 μm. D) The cell viability was measured by MTS assay. Data are presented as the mean ± S.D. *P < 0.05 vs. control, #P < 0.05 vs. CVB-D groups, n = 3.

Fig. 5. CVB-D inhibited the phosphorylation of Akt and mTOR. MCF-7 cells were treated with CVB-D (1, 10, 100 μM) for 30 min. The protein levels of Akt, mTOR, phospho-Akt (p-Akt), and phospho-mTOR (p-mTOR) were each determined by western blot. Representative bands are shown (left panels). The relative protein expression was normalized by α-tubulin (right panels). Data are presented as the mean ± S.D. *P < 0.05 vs. control, n = 3.
has been recognized that carcinogenesis is related to decreased levels of basal autophagy. Emerging evidence suggests that the induction of autophagy is a promising therapeutic strategy in cancer treatment. Numerous anti-cancer drugs, such as curcumin, Hirsutanol A, resveratrol, and soybean B-group, have now been identified to exert their cytotoxic actions by inducing autophagic cell death (25–28). Our present study showed that CVB-D, an active compound extracted from a traditional Chinese herb, could promote autophagy in MCF-7 cells, thereby indicating its potential against cancer.

In this study, MTS assay showed that CVB-D induced MCF-7 cell death in a concentration- and time-dependent manner, which was accompanied with parallel increases in the level of autophagy. Here, double membranelle enclosing autophagosomes were identified in CVB-D–treated MCF-7 cells compared to control cells by using TEM. The MDC staining further confirmed a marked activity of autophagy with accumulation of autophagosomes in MCF-7 cells following CVB-D treatment. It’s known that LC3, a mammalian homologue of ATG8 essential for autophagy in yeast, is recruited to the autophagosome membrane in an ATG5-dependent manner (21). Therefore, autophagosome membrane association of LC3 is a specific marker for autophagy. LC3 puncta formation, as assessed by immunofluorescence, revealed a clear accumulation in the CVB-D–treated cells; and the GFP-tagged LC3–expressing cells were also used to demonstrate induction of autophagy. GFP-LC3 cells presented a diffuse distribution in the control, while a punctate pattern of GFP-LC3 was increased in number and fluorescence intensity by CVB-D. Since LC3 is associated with the formation of autophagosomes through the conversion of LC3-I (cytosolic) to LC3-II (membrane bound), the amount of LC3-II correlates well with the number of autophagosomes and is a well-established indicator of autophagosome formation (29–30). Moreover, the recruitment of LC3 to the membrane occurs via an ATG5-dependent mechanism, and thus ATG5 is essential for autophagosome formation. Western blot analysis revealed that CVB-D significantly up-regulated expressions of both LC3-II and ATG5, further indicting CVB-D–induced autophagy in MCF-7 cells.

To explore whether autophagy was involved in the cytotoxicity of CVB-D, the autophagy specific inhibitor 3-MA was used. It has been well established that 3-MA blocks autophagic cell death by inhibiting class III phosphatidylinositol 3-kinase (PI3K) (4). The results of Western blotting and MDC staining showed that autophagy promoted by CVB-D was significantly attenuated by 3-MA. Although 3-MA alone had no toxic effect on MCF-7 cells, it reversed the decrease in cell viability in CVB-D–treated cells. Convergently, these findings suggested CVB-D–induced cell death at least partially through triggering autophagy.

Recent research indicated that the PI3K–Akt–mTOR pathway, which is activated in many types of cancer, is important in autophagy (31). PI3K is a conserved family of lipid kinases that produce lipids involved in cell proliferation, differentiation, apoptosis, autophagy, cytoskeletal organization, and membrane trafficking (32–34). Three classes of PI3K have been defined so far. Class I PI3K is involved in the inhibitory effect on autophagy, while the class III PI3K is involved in the sequestration of cytoplasmic material in autophagy (35). Akt is a serine-threonine kinase, located downstream of class I PI3K, that activates the kinase mTOR, leading to suppression of autophagy (31). As a key negative regulator of autophagy, mTOR lies upstream of all autophagy-associated genes. It, in response to the nutrient levels available to the cell, can inhibit unc-51-like kinase 1 (ULK1) and ATG13 by phosphorylation (36). It is also revealed that mTOR exerts a further brake on autophagy by directly phosphorylating activating molecule in Beclin 1–regulated autophagy (AMBRA1) (37). Rapamycin, which inhibits the mTOR signaling pathway, induces autophagy and inhibits the proliferation of malignant glioma cells (38). Pre-clinical and preliminary clinical studies have demonstrated that targeting mTOR signaling with rapamycin and its analogues is therefore a potent selective therapeutic strategy for many tumor types (38–39). Our data showed that CVB-D did not affect the protein expression of Akt and mTOR, but the phosphorylation of these two proteins significantly decreased following CVB-D treatment. Although mTOR-independent activation of autophagy cannot be excluded, it suggests that inhibition of the Akt–mTOR axis may be involved in autophagic cell death induced by CVB-D.

Taken together, the present work provides evidence that CVB-D promotes autophagic cell death in MCF-7 cells, thereby supporting the potential application of CVB-D in cancer therapy. Certainly, further investigations are required to confirm and clarify the regulation of the PI3K–Akt–mTOR pathway by CVB-D. In vivo studies using cancer animal models are now undergoing in our lab.

**Acknowledgments**

This work was supported by grants from the National Natural Science Foundation of China (No. 81072641, No. 81273499, No. 81200096); the National Science and Technology Major Project of China “Key New Drug Creation and Manufacturing Program” (No. 2011ZX09401-307); Team item of Natural Science Foundation of Guangdong Province (No. S2011030003190); and Major Project of...
Department of Education of Guangdong Province (No. CXZD1006), Guangdong Science Foundation (2012A080201007), and Major Project of Guangzhou City (No. 2011Y1-00017).

Conflicts of Interest
No conflicts of interest are declared by the authors.

References
32. Liu Y, Shi QF, Ye YC, Tashiro S, Onodera S, Ikejima T. Activated O-2(center dot-) and H2O2 mediated cell survival in SU11274-


